Inactive Instrument

RESP HEAL

Equities

RAP

AU000000RAP5

ResApp Appoints Michael Stein as Non-Executive Director

April 05, 2020 at 07:02 pm EDT

ResApp Health Limited announced the appointment of Dr Michael Stein as a Non-Executive Director, effective immediately. Michael is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, Michael was the founding CEO of OxStem Ltd, an award-winning biotechnology spin-out from the University of Oxford.

Latest news about RESP HEAL

Pfizer Australia Holdings Pty Limited completed the acquisition of ResApp Health Limited.	22-09-14	CI
ResApp Health Secures Shareholder Approval for Takeover Scheme	22-09-07	MT
ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
ResApp Health Limited Auditor Raises 'Going Concern' Doubt	22-08-28	CI
ResApp Health Validates Effectivity of Respiratory Diagnostic App in Mask-Wearing Patients; Shares Fall 4%	22-07-21	MT
ResApp Health Secures Court Orders for Scheme Deal	22-07-15	MT
ResApp Health Agrees to One-Year Extension of Commercial License Deal	22-07-08	MT
ResApp Health Limited Agrees to 12 Month Extension to its Commercial Licence Agreement with Medgate AG	22-07-06	CI
ResApp Health Secures US FDA Medical Device Clearance for Sleep Apnea Software	22-07-06	MT
ResApp Health Limited Receives FDA 510(K) Clearance for Sleepcheckrx	22-07-05	CI
ResApp Health Gets Australian, Japanese Patents for Cough Detection Technology	22-07-04	MT
ResApp Health Limited Announces Results from Data Confirmation Study	22-06-20	CI
Pfizer Sweetens Offer to Acquire Australian ResApp Health	22-06-14	MT
Transcript : ResApp Health Limited, Q3 2022 Earnings Call, Apr 26, 2022	22-04-25
ResApp Has Entered into A Research & Development Licence Agreement with Pfizer	22-04-10	CI
Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited for approximately AUD 100 million.	22-04-10	CI
Transcript : ResApp Health Limited - Special Call	22-04-07
ResApp Health Signs Deal for Pilot Testing of Respiratory Diagnostic App in the UK	22-03-31	MT
ResApp Health Limited Signs One Year Agreement with the Dartford and Gravesham National Health Service	22-03-31	CI
ResApp Health's Cough-based Diagnostic Test Achieves 92% Sensitivity Rate for COVID-19 Detection in Trial	22-03-22	MT
Transcript : ResApp Health Limited - Special Call	22-03-21
ResApp Health Limited Announces Positive Results of Covid-19 Screening Test	22-03-21	CI
ResApp Health Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-24	CI
Resapp Health, Health Teams to Launch ResAppDx on Aged Care Telehealth Platform	22-02-14	MT
Health Teams to Launch ResAppDx on Aged Care Platform	22-02-13	CI

Chart RESP HEAL

Duration

Period

More charts

Company Profile

ResApp Health Limited is an Australia-based digital health company engaged in developing smartphone applications for the diagnosis and management of respiratory disease. The Company provides point of care diagnostic solutions for telehealth that are integrated into existing platforms. The Company is focused on developing apps to provide instant clinical diagnostic tests and management tools directly to consumers and healthcare providers. The Company's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. Its products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Its obstructive sleep aponia screening test uses overnight breathing and snoring sounds recorded on a smartphone.

Sector

More about the company